Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 28, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Plasmablastic lymphoma: a review.

P Rafaniello Raviele1, G Pruneri, E Maiorano

  • 1Division of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan, Milan, Italy.

Oral Diseases
|October 23, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of the molecular tumor board: learnings from the ROME trial.

NPJ precision oncology·2026
Same author

A tailored histology-driven molecular profiling algorithm proposal for salivary gland cancers.

ESMO open·2026
Same author

HER2-low breast cancer is immune-cold: insights into tumor-infiltrating immune cells and implications for immunotherapy.

NPJ breast cancer·2025
Same author

Impact of molecular tests and precision oncology on patients with advanced thyroid carcinomas in a referral center: the OrienTHYring real-world study.

ESMO open·2025
Same author

Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Plasmablastic lymphoma (PBL) is an aggressive non-Hodgkin's lymphoma often found in HIV-infected individuals. This rare cancer has a poor prognosis, with a high mortality rate within a year of diagnosis.

Area of Science:

  • Oncology
  • Hematology
  • Infectious Diseases

Background:

  • Plasmablastic lymphoma (PBL) is an aggressive non-Hodgkin's lymphoma subtype.
  • It predominantly affects the oral cavity in HIV-infected patients.
  • Approximately 60 cases have been reported, characterized by specific cellular morphology and immunophenotype.

Purpose of the Study:

  • To characterize the clinico-pathological features of Plasmablastic Lymphoma.
  • To explore potential pathogenetic roles of viral agents in PBL.
  • To review treatment strategies and outcomes for PBL patients.

Main Methods:

  • Histopathological examination of tumor samples.
  • Immunohistochemical analysis for CD138 expression.
  • Molecular analysis of immunoglobulin gene rearrangements (IgH/IgL).

More Related Videos

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

Related Experiment Videos

Last Updated: Jun 28, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

  • Review of clinical data, treatment regimens, and patient outcomes.

    • Main Results:

    • PBL exhibits large cells with specific nuclear and cytoplasmic features.
    • Tumor cells consistently express CD138 and demonstrate immunoglobulin gene clonality.
    • Epstein-Barr virus and HHV-8 are implicated in PBL pathogenesis.
    • Treatment approaches are heterogeneous, including chemotherapy, radiotherapy, and surgery.

    Conclusions:

    • PBL is a distinct and aggressive lymphoma subtype with a poor prognosis.
    • Viral co-infections may contribute to PBL development in immunocompromised individuals.
    • Effective treatment strategies and improved outcomes for PBL remain a significant challenge.